Tavalisse
Payments companies reported to CMS as associated with Tavalisse. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Tavalisse, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Tavalisse
These are the largest totals companies reported as associated with Tavalisse. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| Joseph Bailes | Mckinney, TX | $168,040.67 | |
| Amit Mehta | Cary, NC | Hematology & Oncology | $92,428.56 |
| Satheesh Kathula | Kettering, OH | Hematology & Oncology | $91,762.70 |
| Praneeth Baratam | Charleston, SC | Hematology (Internal Medicine) | $67,379.07 |
| Suresh Ratnam | Mcallen, TX | Medical Oncology | $66,831.57 |
| Slawomir Wojtowicz-Praga | South San Francisco, CA | Medical Oncology | $66,000.00 |
| James Mccloskey | Hackensack, NJ | Medical Oncology | $60,783.13 |
| Aron Kefela | Hiram, GA | Hematology & Oncology | $58,199.69 |
| Binay Shah | Sequim, WA | Hematology & Oncology | $57,500.00 |
| George Yaghmour | Los Angeles, CA | Hematology & Oncology | $55,302.64 |
Prescribed Tavalisse?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.